🟢 Senti Biosciences is trading 6.4% up in pre-market after positive Moderna-Merck Phase 3 melanoma-vaccine results

Senti Biosciences is trading 6.4% up now at $0.49 after biotechnology shares rallied following positive Phase 3 melanoma-vaccine results from Moderna and Merck.

• The trial met recurrence-free-survival and distant-metastasis-free-survival goals, prompting a broad oncology and vaccine-stock sympathy move.
• No fresh company-specific announcement for August 20, 2026 was identified; the move appears primarily sector-driven rather than tied to new Senti Biosciences fundamentals.